ETF Holdings Breakdown of NBIX

Stock Name	Neurocrine Biosciences Inc
Ticker	NBIX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US64125C1099
LEI	549300FECER0XBN49756

NBIX institutional holdings

The following institutional investment holdings of NBIX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-27	IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc))	173,658	USD 26,323,080	151.58
2025-11-27	IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist))	173,658	USD 26,323,080	151.58
2025-11-27	IE00BKBF6H24 (iShares Core MSCI World UCITS ETF)	173,658	USD 26,323,080	151.58
2025-11-27	IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist))	173,658	USD 26,323,080	151.58
2025-11-27	IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist))	17,492	USD 2,651,437	151.58
2025-11-27	IE00B6R52259 (iShares MSCI ACWI UCITS ETF)	26,815	USD 4,064,618	151.58
2025-11-24	IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc))	26,689 0.2%	USD 3,769,821 -0.2%	141.25
2025-11-27	IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc))	30,924	USD 4,687,460	151.58
2025-11-27	IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist))	30,924	USD 4,687,460	151.58
2025-11-27	IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc))	30,924	USD 4,687,460	151.58
2025-11-27	IE00BMTX1Y45 (iShares S&P 500 Swap UCITS ETF USD (Acc))	18,565 200.0%	USD 2,814,083 200.0%	151.58
2025-11-27	IE000D3BWBR2 (iShares S&P 500 Swap UCITS ETF USD (Dist))	18,565 200.0%	USD 2,814,083 200.0%	151.58
2025-11-27	IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist))	11,332	USD 1,717,705	151.58
2025-11-27	IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP)	3,415	USD 517,646	151.58
2025-11-27	IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist))	9,168	USD 1,389,685	151.58
2025-11-27	IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF)	9,168	USD 1,389,685	151.58
2025-11-27	IE00B8FHGS14 (iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc))	22,842	USD 3,462,390	151.58
2025-11-27	IE00BGPP8L80 (iShares Edge MSCI World Minimum Volatility UCITS ETF GBP Hedged (Acc))	22,842	USD 3,462,390	151.58
2025-11-27	IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc))	6,161	USD 805,455	130.73
2025-11-27	IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc))	5,476	USD 830,052	151.58
2025-11-27	IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD)	1,782	USD 270,116	151.58
2025-11-27	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	119,003	USD 18,038,475	151.58
2025-11-27	IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF)	1,868	USD 283,151	151.58
2025-11-27	IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc))	1,868	USD 283,151	151.58
2025-11-27	IE00B27YCN58 (iShares MSCI World Islamic UCITS ETF USD (Dist) USD)	4,216	USD 639,061	151.58
2025-11-27	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	67,022	USD 10,159,195	151.58
2025-11-27	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	67,022	USD 10,159,195	151.58
2025-11-27	IE00BN92ZL31 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist))	485	USD 73,516	151.58
2025-11-27	IE00BMXC7W70 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Acc))	485	USD 73,516	151.58
2025-11-27	IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc))	683	USD 78,135 -0.2%	114.40
2025-11-27	IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc))	3,284	USD 497,789	151.58
2025-11-27	IE00BD1F4K20 (iShares MSCI USA Mid-Cap Equal Weight UCITS ETF USD (Acc))	6,756	USD 1,024,074	151.58
2025-11-27	IE00B296QM64 (iShares MSCI USA Islamic UCITS)	2,328	USD 352,878	151.58
2025-11-27	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,424	USD 215,850	151.58
2025-11-27	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	126	USD 19,099	151.58
2025-11-27	IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc)	186	USD 28,194	151.58
2025-11-27	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	5,761	USD 873,252	151.58
2025-11-27	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	5,068	USD 768,207	151.58
2025-11-27	IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP)	3,415	USD 517,646	151.58
Total =	1,278,716	USD 193,398,250

News associated with NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Maryland State Retirement & Pension System: Maryland State Retirement & Pension System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the company’s stock after selling 663 shares during the quarter. Maryland […] - 2025-08-15 05:24:56
Charles Schwab Investment Management Inc. Purchases 13,216 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 775,773 shares of the company’s stock after acquiring an additional 13,216 shares during the quarter. Charles […] - 2025-08-13 05:10:46
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Blair William & Co. IL: Blair William & Co. IL cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.7% in the first quarter, Holdings Channel reports. The fund owned 6,214 shares of the company’s stock after selling 242 shares during the period. Blair William & Co. IL’s holdings in Neurocrine Biosciences were worth $687,000 at the […] - 2025-08-11 05:52:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Federated Hermes Inc.: Federated Hermes Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 72.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,441 shares of the company’s stock after selling 25,402 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-07 05:22:58
Natixis Advisors LLC Sells 292 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Natixis Advisors LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 33,312 shares of the company’s stock after selling 292 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,684,000 at the end of the […] - 2025-08-07 04:49:07
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript: @media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo - 2025-08-05 01:16:10
Neurocrine (NBIX) Q2 Revenue Jumps 17%: Key PointsNon-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. - 2025-08-01 01:15:16
13,202 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Y Intercept Hong Kong Ltd: Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 13,202 shares of the company’s stock, valued at approximately $1,460,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. […] - 2025-07-24 06:50:57
HighPoint Advisor Group LLC Purchases 366 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): HighPoint Advisor Group LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 15.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,812 shares of the company’s stock after acquiring an additional 366 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Neurocrine Biosciences were worth $302,000 […] - 2025-07-24 05:51:14
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Analysts at Truist Financial: Truist Financial initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $163.00 price target on the stock. NBIX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and […] - 2025-07-22 04:28:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Cerity Partners LLC: Cerity Partners LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,361 shares of the company’s stock after selling 8,376 shares during the quarter. Cerity Partners LLC’s holdings in […] - 2025-07-18 04:55:08
Ingrid Delaet Sells 457 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares in the […] - 2025-07-14 07:16:47
Bank of New York Mellon Corp Has $91.65 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Bank of New York Mellon Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.8% during the first quarter, HoldingsChannel reports. The fund owned 828,682 shares of the company’s stock after selling 41,608 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $91,652,000 as […] - 2025-07-11 05:40:57
Principal Financial Group Inc. Has $27.48 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Principal Financial Group Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,420 shares of the company’s stock after selling 4,049 shares during the period. Principal Financial Group Inc. owned 0.25% of Neurocrine Biosciences […] - 2025-07-09 05:51:40
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 […] - 2025-07-09 03:09:50
First Horizon Advisors Inc. Has $43,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 55.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385 shares of the company’s stock after selling 480 shares during the quarter. First Horizon Advisors […] - 2025-07-08 05:49:06
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 20,362 Shares: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 20,362 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider owned 18,289 shares of the company’s […] - 2025-07-08 05:06:50
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by KBC Group NV: KBC Group NV lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the 1st quarter, Holdings Channel reports. The fund owned 13,835 shares of the company’s stock after selling 495 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,530,000 as of its most recent filing […] - 2025-07-04 06:58:45
New York State Teachers Retirement System Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): New York State Teachers Retirement System lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,481 shares of the company’s stock after selling 2,055 shares during the quarter. New York State Teachers Retirement System’s holdings in Neurocrine Biosciences were worth $11,998,000 […] - 2025-07-04 06:14:58
Amalgamated Bank Has $5.28 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Amalgamated Bank lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,719 shares of the company’s stock after selling 1,895 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were […] - 2025-07-03 06:14:49
Sumitomo Mitsui Trust Group Inc. Sells 1,399 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 231,458 shares of the company’s stock after selling 1,399 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-07-03 05:35:01
Golden State Wealth Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Golden State Wealth Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 116.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397 shares of the company’s stock after purchasing an additional 214 shares during the quarter. […] - 2025-07-02 05:01:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Oppenheimer & Co. Inc.: Oppenheimer & Co. Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,388 shares of the company’s stock after buying an additional 447 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $2,144,000 as […] - 2025-06-27 05:10:49
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Retirement Systems of Alabama: Retirement Systems of Alabama cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.4% in the 1st quarter, Holdings Channel reports. The firm owned 121,352 shares of the company’s stock after selling 1,755 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $13,422,000 at the […] - 2025-06-23 05:04:51
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by QRG Capital Management Inc.: QRG Capital Management Inc. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,062 shares of the company’s stock after buying an additional 1,330 shares […] - 2025-06-20 06:54:59
Sowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company’s stock, valued at approximately $529,000. Other institutional investors and hedge funds […] - 2025-06-20 05:29:06
Trust Point Inc. Sells 660 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Trust Point Inc. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,823 shares of the company’s stock after selling 660 shares during the period. Trust Point Inc.’s holdings in […] - 2025-06-19 05:35:02
XBI, EXAS, NBIX, NTRA: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $443.9 million dollar outflow -- that's a 8.8% decrease week over week - 2025-06-17 11:54:37
Merit Financial Group LLC Acquires 345 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Merit Financial Group LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,153 shares of the company’s stock after purchasing an additional 345 shares during the quarter. Merit Financial Group […] - 2025-06-11 05:00:51
Congress Asset Management Co. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Congress Asset Management Co. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,363 shares of the company’s stock, valued at approximately $261,000. Several other hedge funds also recently modified their […] - 2025-06-10 05:04:58

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.